Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Trial Clinical Hold Will Be Topic Of FDA, NIH Meetings

Executive Summary

FDA's Biological Response Modifiers Advisory Committee and NIH's Recombinant DNA Advisory Committee will each discuss the latest adverse event to occur in a French gene transfer trial at upcoming meetings

You may also be interested in...



Stem Cell Retroviral Gene Therapy Trials May Proceed On Case-By-Case Basis

The 27 hematopoietic stem cell trials in the U.S. that use retroviral vectors should be allowed to proceed on a case-by-case basis based on risk/benefit profiles, FDA's Biologics Response Modifiers Advisory Committee agreed at its Feb. 28 meeting

Stem Cell Retroviral Gene Therapy Trials May Proceed On Case-By-Case Basis

The 27 hematopoietic stem cell trials in the U.S. that use retroviral vectors should be allowed to proceed on a case-by-case basis based on risk/benefit profiles, FDA's Biologics Response Modifiers Advisory Committee agreed at its Feb. 28 meeting

SCID Event Should Be Included In All Retroviral Therapy Informed Consent

All retroviral gene therapy trial informed consent forms should include information about a leukemia-like event that occurred in a recent severe combined immunodeficiency gene therapy trial, FDA's Biological Response Modifiers Advisory Committee recommended Oct. 10

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel